STOCK TITAN

Taro Pharmaceutical Industries Ltd. - $TARO STOCK NEWS

Welcome to our dedicated page for Taro Pharmaceutical Industries Ltd. news (Ticker: $TARO), a resource for investors and traders seeking the latest updates and insights on Taro Pharmaceutical Industries Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taro Pharmaceutical Industries Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taro Pharmaceutical Industries Ltd.'s position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Taro Pharmaceutical Industries Ltd. reports unaudited financial results for Q1 and FY 2023. Net sales increased by 2.3% in Q1 compared to the previous year, while gross profit decreased. R&D expenses and SG&A expenses increased in Q1. Operating income decreased, while interest and other financial income increased. Net income and earnings per share were lower in Q1 compared to the previous year. For FY 2023, net sales increased, but gross profit decreased. R&D expenses decreased, while SG&A expenses increased significantly. Operating income decreased, but excluding settlement charges, it increased. Interest and other financial income increased. Net income and earnings per share were lower in FY 2023 compared to the previous year. Cash flow provided by operations improved in FY 2023 compared to the previous year. Cash and cash equivalents remained stable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
none
-
Rhea-AI Summary
Taro Pharmaceutical Industries Ltd. plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
Taro Pharmaceutical Industries Ltd.

NYSE:TARO

TARO Rankings

TARO Stock Data

1.59B
8.09M
78.48%
13.45%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Haifa

About TARO

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.